Give now

News

  • September 21, 2022
    Meet Research Grant Recipient: Nicholas Norris
    Learn more
  • September 08, 2022
    Meet Research Grant Recipient: Devin McBride, PhD
    Learn more
  • September 01, 2022
    Meet Research Grant Recipient: Melanie Martinez
    Learn more
  • August 30, 2022
    Meet Research Grant Recipient: Mark Johnson, MD
    Learn more
  • August 25, 2022
    Meet Research Grant Recipient: Koji Hosaka, PhD
    Learn more
  • August 24, 2022
    Meet Research Grant Recipient: Louis-Philippe Bernier, PhD
    Learn more
  • August 16, 2022
    Meet Research Grant Recipient: Umeshkumar Athiraman, MD, MBBS
    Learn more
  • August 11, 2022
    Meet Research Grant Recipient: Omid Amili, PhD
    Learn more
  • August 11, 2022
    Meet Research Grant Recipient: Joseph Antonios, MD, PhD
    Learn more
  • June 30, 2022
    ‘I’m a Neurosurgeon Who Can’t Move. Now What?’
    Learn more

In My Area

Support groups
  • AdventHealth Brain Aneurysm Support Group

    Winter Park, FL

    Learn more
  • Baltimore Brain Aneurysm Foundation Support Group

    Lutherville-Timonium, MD

    Learn more
  • Bay Area Aneurysm and Vascular Malformation Support Group

    San Francisco, CA

    Learn more
  • August 04, 2020
  • BAF
  • Technology

Stryker’s Neuroform Atlas Stent System granted an expanded indication

Stryker announced today that it has received U.S. Food and Drug Administration (FDA) approval for an expanded indication of its Neuroform Atlas Stent System, becoming the first and only adjunctive stent approved for use in the posterior (back of the brain) circulation. Aneurysms in the posterior circulation rupture more frequently and are generally more difficult to treat. With the approval of the Neuroform Atlas adjunctive stent for the posterior circulation, long term treatment is more feasible.

Stryker’s Neuroform Atlas® Stent System, which was granted an expanded indication, providing a new option for patients with aneurysms in the back of the brain.

Already approved for use in the anterior circulation, the expanded indication was granted based on robust clinical trial evidence proving the safety and efficacy of the device. The combined patients from both the anterior and posterior cohorts totaled 298 patients, making it the largest study of its kind.

Read full article here

KALAMAZOO, Michigan, USA, Aug. 3, 2020 /PRNewswire



This site uses cookies

Our site uses cookies to personalize features and, via third-parties, to collect metrics on usage so that we can better tailor our site to the needs of our users. You can view our full cookie and privacy policies via the links below. To fully experience our site, please click Accept.